* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
Download BrainPowerPointHealy
Classification of mental disorders wikipedia , lookup
Anxiety disorder wikipedia , lookup
Parkinson's disease wikipedia , lookup
Conduct disorder wikipedia , lookup
Mental disorder wikipedia , lookup
Schizophrenia wikipedia , lookup
Factitious disorder imposed on another wikipedia , lookup
Glossary of psychiatry wikipedia , lookup
Asperger syndrome wikipedia , lookup
Narcissistic personality disorder wikipedia , lookup
Postpartum depression wikipedia , lookup
Panic disorder wikipedia , lookup
Spectrum disorder wikipedia , lookup
Separation anxiety disorder wikipedia , lookup
History of psychiatry wikipedia , lookup
Dissociative identity disorder wikipedia , lookup
History of mental disorders wikipedia , lookup
Bipolar disorder wikipedia , lookup
Conversion disorder wikipedia , lookup
Mental status examination wikipedia , lookup
Schizoaffective disorder wikipedia , lookup
Causes of mental disorders wikipedia , lookup
Bipolar II disorder wikipedia , lookup
Child psychopathology wikipedia , lookup
Major depressive disorder wikipedia , lookup
Biology of depression wikipedia , lookup
Generalized anxiety disorder wikipedia , lookup
Antipsychotic wikipedia , lookup
Emergency psychiatry wikipedia , lookup
Controversy surrounding psychiatry wikipedia , lookup
Substance dependence wikipedia , lookup
Substance use disorder wikipedia , lookup
Alcohol withdrawal syndrome wikipedia , lookup
Daniel Healy, M.D.      Psychotic Disorders  Schizophrenia  Schizoaffective Disorder Mood Disorders  Major Depressive Disorder + psychosis  Bipolar Disorder (Manic-Depression) + psychosis Anxiety Disorders  PTSD  OCD  GAD  Panic Disorder Personality Disorders  Cluster A (Paranoid, Schizoid, Schizotypal  Cluster B (Borderline, Antisocial, Narcissiistic, Histrionic)  Cluster C (Avoidant, Dependent, Obsessive –Compulsive) Substance Abuse Disorders  Problem in certain brain regions that comprise circuits  Frontal lobe- cognition, alertness, control impulses, motivation  Temporal lobe (hippocampus plus)-forming memories, auditory hallucinations  Thalamus-interprets inputs from the five senses  Cingulate gyrus-normal expression of emotions  Caudate-putamen, nucleus accumbens-fine tunes emotions and movements, reward/reinforcement  Parietal lobe-allows you to be aware of your own actions  Amygdala-anxiety, anger  Hypothalamus-sleeping, eating  Problem with certain neurotransmitters (nerves don’t connect, gap is called synapse, neurotransmitters “connect” nerves)  Dopamine-reward/reinforcement, paranoia, substance abuse  Glutamate-ubiquitous, excitatory, too much kills neurons, stress increases cortisol increases glutamate (stress kills nerves), cognition, pain/temperature, affects dopamine release  Serotonin-depression, anxiety, abnormal movements  GABA-ubiquitous, inhibitory, anxiety, cognition  Acetylcholine-memory, cognition, movements, nicotine affects acetylcholine nerves  http://www.brainexplorer.org is a good website; so is www.sharpbrains.com, which puts brain function in the context of investing.  Why it is complicated  Billions of connections  Different brain areas use different neurotransmitters  Neurotransmitters have multiple types of receptors, some having opposite effects for same neurotransmitter  Few medications affect only one neurotransmitter, so can’t control the (side) effects of medications (most selective, least effective)  Homeostasis, tendency to maintain status quo, means that it is hard to drive one area only  Giving a medication to affect one area causes changes in other regions  Genes and environment are both influential   Defined by impaired reality testing Positive symptoms (presence of abnormality):  thought content: delusions  perception: hallucinations  thought stream: grossly disorganized  behavior: grossly disorganized Dopamine imbalance in the frontal lobe and caudate putamen)  Negative symptoms (absence of normality):  Affect blunted or flat  Avolition/amotivation  Alogia: decreased amount or content  Anhedonia: lack of interests Dopamine and glutamate imbalance (too little frontal lobe, too much in caudate putamen, maybe amygdala and hippocampus)  Stimulus flooding  Lack of an effective filter  Too much information from the environment  Leads to withdrawal from social contact  Stimulus overload  Leads to frustration, poor concentration, nervousness Thalamus uses gaba and glutamate to filter info from all five senses            Chlorpromazine Fluphenazine Haloperidol Loxapine Mesoridazine Molindone Perphenazine Pimozide Thioridazine Thiothixene Trifluoperazine Thorazine Prolixin Haldol Loxitane Serentil Moban Trilafon Orap Mellaril Navane Stelazine Haloperidol Decanoate (Haldol)  Fluphenazine Decanoate (Prolixin)      Effective control of psychotic symptoms in responsive patients Reduced need for institutional care Clinical experience Relatively inexpensive, generics available  Lack of efficacy  Negative symptoms (frontal lobe, glutamate)  Depression  Safety and tolerability concerns  Extrapyramidal symptoms / tardive dyskinesia (dopamine/acetylcholine in caudate putamen)  Sedation (frontal lobe)  Cognitive impairments (frontal lobe)  Prolactin elevation (dopamine pituitary)  Cardiovascular symptoms (arrhythmias)  Nonadherence           clozapine risperidone olanzapine quetiapine ziprasidone aripiprazole paliperidone ileoperidone asenapine lurasidone (Clozaril) (Risperdal) (Zyprexa) (Seroquel) (Geodon) (Abilify) (Invega) (Fanapt) (Saphris) (Latuda) 1990 1994 1996 1997 2001 2002 2006 2009 2009 2011      clozapine (Fazaclo) risperidone (Risperdal M-tabs) olanzapine (Zyprexa Zydis) aripiprazole (Abilify Discmelt) asenapine (Saphris is sublingual) risperidone Consta (Risperdal)  paliperidone Sustenna (Invega)  olanzapine Relprevv (Zyprexa) (Watch out for  coma. Seriously.)        At least as effective as conventional agents Shift the risk / benefit ratio The EPS advantage (serotonin) Reduced risk of tardive dyskinesia (dopamine serotonin) Broader symptom efficacy May enhance compliance, reduce hospitalizations, be cost-effective Challenge providers to deliver effective rehabilitation services      Expensive Weight gain, diabetes, cholesterol Sedating (histamine) Sometimes not efficacious against positive symptoms (dopamine) Seroquel can be a drug of abuse      Life expectancy increasing in general population (when controlling for infant mortality) Life expectancy still around 55 for folks diagnosed with schizophrenia Lifestyle improvements not adopted by the people we serve (exercise, nutrition, smoking) Access to healthcare Weight gain from medications      Sad, irritable or empty mood Diurnal variation Diminished capacity for enjoyment Diminished interests Frontal lobe, serotonin, norepinephrine, dopamine (anhedonia)     Difficulty concentrating Indecisiveness Memory problems Depressed content of thought     Worthlessness Guilt Hopelessness Death and Suicide Frontal lobe, serotonin, norepinephrine       Sleep disturbances Appetite disturbances, weight changes Fatigue, low energy Upset stomach, constipation Physical pain Hypothalamus serotonin, norepinephrine, histamine (sleep)  Mild to severe  May include psychosis, poor self care, suicide  Abraham Lincoln describing his own depression:  “I am now the most miserable man living. If what I feel were equally distributed to the whole human family, there would not be one cheerful face on earth. Whether I shall ever be better, I cannot tell. I awfully forebode I shall not. To remain as I am is impossible. I must die or be better, it appears to me.”   All antidepressants must be taken for at least 4-6 weeks to have substantial benefit Studies are showing that if you don’t respond in the first week or two, you’re probably not going to, so augment or change earlier than previously recommended.  Problem in certain brain regions that comprise circuits       Frontal lobe- mood, cognition, alertness, motivation Cingulate gyrus-normal expression of emotions Caudate-putamen-fine tunes emotions and movements Amygdala-anxiety, anger Hypothalamus-sleeping, eating Hippocampus-memory  Dopamine-reward/reinforcement, anhedonia  Glutamate-ubiquitous, excitatory, too much kills neurons, stress increases cortisol increases glutamate (stress kills nerves), cognition, affects dopamine release  Serotonin- all aspects of depression  Norepinephrine- all aspects of depression  GABA-ubiquitous, inhibitory, anxiety, cognition  Acetylcholine-memory, cognition,       Fluoxetine (Prozac) Sertraline (Zoloft) Paroxetine (Paxil) Citalopram (Celexa) Escitalopram (Lexapro) Fluvoxamine (Luvox)         Nausea Dry mouth Diarrhea or stomach upset Lack of appetite Feeling tired, weak, or dizzy Headache Anxiety or nervousness Sexual dysfunction  Bupropion (Wellbutrin, Zyban)  Can cause agitation, anxiety, insomnia  Venlafaxine (Effexor, Pristiq)  Hypertension, SSRI-like side effects  Trazodone (Desyrel)  Sedation, dizziness  Nefazodone (Serzone)  SSRI-like but more sedation, monitor for liver toxicity  Mirtazapine (Remeron)  May cause sedation, weight gain  Duloxetine (Cymbalta)  May cause nausea       Amitriptyline (Elavil) Clomipramine (Anafranil) Desipramine (Norpramin) Doxepin (Sinequan) Imipramine (Tofranil) Nortriptyline (Pamelor)        Can be fatal in overdose Fatigue, sedation Light-headedness, dizziness Dry mouth Constipation Weight gain Headache      Isocarboxazid (Marplan) Meclobemide (Aurorix) Phenelzine (Nardil) Tranylcypromine (Parnate) Selegiline (Eldepryl)  Strict dietary restriction  Avoid aged cheeses and meats, soy sauce, soy beans, fava beans, wine, beer, others   Avoid other anti-depressants Avoid over-the-counter medications       Hypertensive crisis Serotonin syndrome Weight gain Fatigue Constipation Dizziness          1% of general population Equal in men and women Age of onset similar to schizophrenia Episodes can come on very fast (1-7 days) Later episodes longer, more severe, more frequent Substance abuse common Heredity plays a greater role than in depression Family members also at higher risk for major depression High suicide risk   Persistently elevated, expansive or irritable mood for one week Associated symptoms (need 3 or more for diagnosis)        Inflated self -esteem or grandiosity Decreased need for sleep More talkative Racing thoughts or flight of ideas Distractibility Agitation or increase in activities Excessive involvement in pleasurable activities with a high risk for painful consequences  Spending sprees, sexual indiscretions, foolish investments  Distinct period of persistently elevated, expansive, or irritable mood, lasting throughout at least 4 days plus three of the following:  inflated self-esteem or grandiosity  decreased need for sleep (e.g., feels rested after only 3 hours of sleep)  more talkative than usual or pressure to keep talking  flight of ideas or subjective experience that thoughts are racing  distractibility (i.e., attention too easily drawn to unimportant or irrelevant external stimuli)  increase in goal-directed activity (either socially, at work or school, or sexually) or psychomotor agitation  excessive involvement in pleasurable activities that have a high potential for painful consequences (e.g., engaging in unrestrained buying sprees, sexual indiscretions, or foolish business investments)  The criteria are met both for a Manic Episode and for a Major Depressive Episode (except for duration) nearly every day during at least a 1-week period.  B. The mood disturbance is sufficiently severe to cause marked impairment in occupational functioning or in usual social activities or relationships with others, or to necessitate hospitalization to prevent harm to self or others, or there are psychotic features.  C. The symptoms are not due to the direct physiological effects of a substance (e.g., a drug of abuse, a medication, or other treatment) or a general medical condition (e.g., hyperthyroidism).      Frontal lobe and amygdala-emotion regulation Impulsivity-dopamine reward/reinforcement Lack of need for sleep-histamine Increased neuronal firing, glutamate Mood stabilizers may reduce the chemicals produced after a nerve fires  FDA Approved Agents             lithium (Eskalith, Lithobid) (mania, depression) valproate (Depakote) (mania) carbamazepine XR (Tegretol XR) (mania) aripiprazole (Abilify) (mania) asenapine (Saphris) (mania) chlorpromazine (Thorazine) (mania) olanzapine (Zyprexa) (mania) olanzapine + fluoxetine (depression) lamotrigine (Lamictal) (depression prevention) risperidone (Risperdal) (mania) quetiapine (Seroquel) (depression, mania) ziprasidone (Geodon) (mania)  Toxic in overdose  Severe tremor, confusion, disorientation, seizure, coma     Can check blood levels Tremor Gastrointestinal symptoms Increased weight      Monitor blood levels Stomach upset Weight gain Sedation Liver failure  Yellowing of skin or eyes, dark urine, nausea/vomiting  Pancreatitis  Abdominal pain, nausea/vomiting, decreased appetite   Polycystic Ovary risk Hair loss  Other anticonvulsants      Oxcarbazepine (Trileptal) Topiramate (Topamax) Tiagabine (Gabitril) Gabapentin (Neurontin) Other second generation antipsychotics  iloperidone (Fanapt)   Conventional neuroleptics Benzodiazapines  Posttraumatic Stress Disorder  Obsessive Compulsive Disorder  Generalized Anxiety Disorder  Panic Disorder with or without agoraphobia     SSRIs, SNRIs, TCAs effective in concert with psychotherapy Amygdala mediates fear and anxiety, GABA+glutamate balance, norepinephrine, dopamine, serotonin Frontal lobe mediates increased attention/vigilance, norepinephrine Hypothalamus-blood pressure, increased heart rate       Fluoxetine (Prozac) Sertraline (Zoloft) Paroxetine (Paxil) Citalopram (Celexa) Escitalopram (Lexapro) Fluvoxamine (Luvox)  Bupropion (Wellbutrin, Zyban)  Can cause agitation, anxiety, insomnia  Venlafaxine (Effexor, Pristiq)  Hypertension, SSRI-like side effects  Trazodone (Desyrel)  Sedation, dizziness  Nefazodone (Serzone)  SSRI-like but more sedation, monitor for liver toxicity  Mirtazapine (Remeron)  May cause sedation, weight gain  Duloxetine (Cymbalta)  May cause nausea      Alprazolam (Xanax) Chlordiazepoxide (Librium) Clonazepam (Klonopin) Diazepam (Valium) Lorazepam (Ativan)      Oxazepam (Serax) Temazepam (Restoril) Triazolam (Halcion) Zolpidem (Ambien) Zaleplon (Sonata) Note: all have addiction potential, last four mostly for sleep, GABA in amygdala a major target 50     Sedation Addiction potential Can be fatal in overdose, especially if combined with alcohol Studies show most likely outcome for adding a benzo is to create benzo dependence; either no benefit or trigger for abusing other substances 51    Severe craving lengthens tapering off period Taking benzos decreases craving for benzos, alcohol, or other substance of abuse, but does not improve illness Folks with bipolar disorder and depression have a very high risk of developing benzo abuse/dependence, with no evidence that benzos beneficial for mood 52   Many states are restricting or eliminating benzos from formulary Time-limited, supervised use for detox/withdrawal and akasthisia now only acceptable use for benzos 53       Intending to use the substance Hoping not to get in trouble Make bad choices Do get in trouble Outcome goal- abstinence or non-harmful use Dopamine in nucleus accumbens, amygdala frontal lobe, temporal lobe (withdrawal balance of GABA and glutamate) 54  Achieve abstinence before treating mood, anxiety or psychotic disorder 55  Psychotropic medications reduced the likelihood of sobriety 56  No medications available to facilitate sobriety (Antabuse-no data on sobriety) 57  Treat all illnesses simultaneously, and combine medications designed to enhance sobriety with psychosocial interventions 58  Harm reduction is a useful treatment goal as part of the treatment plan. 59  Comorbidity is the expectation, not the exception  Persons diagnosed with schizophrenia  47% use substances  55% of those in psychiatric treatment  Bipolar disorder  62% have substance use disorder  Bipolar consumers more likely to abuse alcohol and cannabis than MDD  Major Depressive disorder  More likely to have alcohol dependence than abuse  Consumers with mood disorders, in general, are likely to abuse benzodiazepines. 60        Provision for basic needs Assertive community treatment (ACT) Patient and family psychoeducation Vocational rehabilitation Clubhouses Social skills training Support groups 61        Motivational enhancement therapy Cognitive behavioral (relapse prevention) 12 step programs Contingency management Family interventions Self-help manuals/workbooks Case management 62   There is little evidence that there is a gene that increases likelihood that you will have a cooccurring disorder There is also little evidence that any one factor “causes” you to develop co-occurring disorder (e.g. personality disorder, “addictive personality”). 63  There is little agreement whether mood disorder symptoms precede or follow substance abuse 64    NO (most of the time) Treat both conditions simultaneously Yearly schizophrenia relapse rate  With medication - 15-20%  Without medication - 70%  Without medication and with precipitant such as substance abuse – greater than 70% 65        With deinstitutionalization, more choices including selfdetermination Not just to self-medicate symptoms Relieves feelings of isolation, loneliness, boredom and despair Facilitates peer interaction and social engagement Promotes a sense of well-being, escape from life perceived as bleak or hopeless, mitigates withdrawal Harder to modify behavior if have cognitive impairments Increases metabolism, effectively reducing doses of medications 66  disulfiram (Antabuse)  Works by interfering with alcohol metabolismcousin of formaldehyde accumulates in blood, causing illness Doesn’t affect craving directly, limited data on relapse reduction More of an aversive treatment 67 Avoid alcohol in any form (aftershave, etc)     naltrexone (Revia)  Works by affecting endogenous opioid system Reduces craving Will induce withdrawal if consumer using or abusing opiates Can’t use opiates for pain management    68  injectible naltrexone (Vivitrol)  Works by affecting endogenous opioid system Reduces craving Will induce withdrawal if consumer using or abusing opiates Can’t use opiates for pain management    69  acamprosate (Campral)  Works by affecting glutamate and/or GABA receptors May reduce craving by mitigating early withdrawal, and reduces relapse rates Avoid if consumer has kidney problems   70  methadone (Dolophine)  Works by occupying opiate receptors in same way morphine and its cousins do Will reduce withdrawal symptoms but some abuse potential Needs to be prescribed in a subspecialty clinic   71  buprenorphine (Suboxone)  Works by occupying opiate receptors without fully stimulating them Will reduce withdrawal symptoms and may have less abuse potential than methadone Prescribers must go through special training in order to prescribe   72  imipramine (Tofranil)  Used to treat depression in consumer with opiate abuse/dependence Treatment for depression with imipramine was associated with reduced craving for, and selfreported use of, opiates, cocaine, and cannabis  73  Nicotine replacement  Works same way smoking and dipping does May reduce craving by occupying and stimulating receptors Available in multiple delivery systems   74  buproprion (Zyban, Wellbutrin)  Works through the dopamine and norepinephrine system (presumably) May reduce craving indirectly Effect independent of antidepressant effect   75  Varenicline (Chantix)  Works by occupying nicotinic receptors, blocking nicotine effects May reduce craving by mildly stimulating receptors Nicotinic receptors are odd: initially stimulated, then shut down Insomnia, agitation, psychosis possible    76      No medication approved for caffeine use/abuse Caffeine blocks adenosine Adenosine receptors in brain affect wakefulness Adenosine receptors in the heart regulate rhythm Adenosine receptors in stomach affect acid secretion 77   Consumers on clozapine seem to have lower rates of substance abuse Lithium for adolescents seems to reduce alcohol abuse 78    Withdrawal from alcohol and benzos can be fatal Withdrawal from opiates is very uncomfortable, with significant physical symptoms, but rarely fatal Withdrawal from cocaine rarely requires close supervision 79  Accessible  Flexible  Capable  Individualized  Comprehensive  Willing and Tolerant  Continuous  Culturally competent  Integrated  Safe housing  Meaningful daytime activity  Sober support network  Positive alliance with at least one treatment provider  Social work interventions reduce stress, preserving brain function, and leading to better outcomes  Can’t remember  Don’t have an illness, so don’t need medications  Difficult medication schedule  Stigma of taking a psychiatric medication  Don’t like/trust the prescriber  The meds aren’t working    Fear of medications Bad side effects No social support Conditions that may be related to problems with brain regions that mediate facial recognition Capgras-delusion that family and friends are imposters Fregoli-delusion that one person is wearing many disguises, so multiple people are actually just one person Cotard-delusion that all of organs are gone or they are dead Autism and Aspergers-interpersonal difficulties may be related to inability to recognize facial expressions Depersonalization-delusion that the face in the mirror is not you  Denial-you understand, on some level, your actions and consequences, but this understanding does not influence behavior  Anosognosia or lack of insight is the physical inability to understand your actions while sick  Anosognosia is more similar to amnesia than to denial        Coercion assumes that the role of the treatment team is to be right and to minimize risk liabilities Therefore, take the steps necessary to optimize a narrowly defined outcome (e.g. suicide prevention) Hospitalization and symptom improvement most likely interventions when suicide risk acutely increased Both are independent risk factors for completed suicide, so…what are we doing? Recovery is a civil rights movement similar to the advances made by the physically disabled to (re-)integrate into the community Society created accommodations for physically disabled (ramps, automatic doors, etc) so they could participate in society Accommodations for the mentally ill were not included in this movement, necessitating a separate movement  Basic tenets of the recovery movement include hope, engagement, supporting self-efficacy, and the dignity of risk  Treatment providers should take a consultative, rather than directive, role in the treatment of psychiatric illnesses; fewer appointments, and more walkin availability  Note that recovery is not a synonym for symptom remission; consumers can be symptomatic and still participate in society  The role of any health care intervention is to shift the odds in your favor; ownership of outcomes cannot rest solely on health care providers  Psychiatric illness associated with increased mortality (life expectancy in your 50s), even when suicide excluded; so…what are we doing?      Some have argued that coercive treatment is an accommodation for asognosia (lack of insight into need for treatment) Others have argued that coercive treatment is a legitimate engagement tool, but should not be relied upon for prolonged periods of time Still others argue that ATOs and recovery can never be reconciled, and they are even against involuntary hospitalization Intensive outreach and engagement are the keys to recovery; court orders merely obligate staff to do the job they should be doing anyway (and without resorting to restrictions of liberty) Do ATO’s reduce or increase autonomy?  Treatment Advocacy Center: “Severe mental illness, not its treatment, restricts civil liberties. By assuring timely and effective intervention for the disabling medical condition of severe mental illness, assisted outpatient treatment restores the capacity to exercise civil liberties and reduces the likelihood of the loss of liberty or life as a result of arrest, incarceration, hospitalization, victimization, suicide and other common outcomes of non-treatment.” Thanks for your time Thanks for your time!  Shout out to Dr Tom Coles, for finishing the Detroit Free Press/Talmer Bank Marathon and raising awareness for the Brain & Behavior Research Foundation (formerly NARSAD)
 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
									 
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                             
                                            